Zamper Raffael P C, Amorim Thiago C, Queiroz Veronica N F, Lira Jordana D O, Costa Luiz Guilherme V, Takaoka Flavio, Juffermans Nicole P, Neto Ary S
Department of Transplant Anesthesia, Hospital Israelita Albert Einstein, Rua Galeno de Almeida 107 ap 172-A, Pinheiros, SP, 05410-030, Brazil.
Resident of the Anesthesiology Program, Hospital Israelita Albert Einstein, São Paulo, Brazil.
BMC Anesthesiol. 2018 Dec 22;18(1):198. doi: 10.1186/s12871-018-0664-8.
Perioperative bleeding and transfusion are important causes of morbidity and mortality in patients undergoing liver transplantation. The aim of this study is to assess whether viscoelastic tests-guided therapy with the use of synthetic factor concentrates impact transfusion rates of hemocomponents in adult patients undergoing liver transplantation.
This is an interventional before-after comparative study. Patients undergoing liver transplantation before the implementation of a protocol using thromboelastometry and synthetic factor concentrates were compared to patients after the implementation. Primary outcome was transfusion of any hemocomponents. Secondary outcomes included: transfusion of red blood cells (RBC), fresh frozen plasma (FFP), cryoprecipitate or platelets, clinical complications, length of stay and in-hospital mortality.
A total of 183 patients were included in the control and 54 in the intervention phase. After propensity score matching, the proportion of patients receiving any transfusion of hemocomponents was lower in the intervention phase (37.0 vs 58.4%; OR, 0.42; 95% CI, 0.20-0.87; p = 0.019). Patients in the intervention phase received less RBC (30.2 vs 52.5%; OR, 0.21; 95% CI, 0.08-0.56; p = 0.002) and FFP (5.7 vs 27.3%; OR, 0.11; 95% CI, 0.03-0.43; p = 0.002). There was no difference regarding transfusion of cryoprecipitate and platelets, complications related to the procedure, hospital length of stay and mortality.
Use of a viscoelastic test-guided transfusion algorithm with the use of synthetic factor concentrates reduces the transfusion rates of allogenic blood in patients submitted to liver transplantation.
This trial was registered retrospectively on November 15th, 2018 - clinicaltrials.gov - Identifier: NCT03756948.
围手术期出血和输血是肝移植患者发病和死亡的重要原因。本研究的目的是评估使用合成凝血因子浓缩物的粘弹性试验指导治疗是否会影响成年肝移植患者血液成分的输血率。
这是一项干预前后的对比研究。将在使用血栓弹力图和合成凝血因子浓缩物的方案实施前接受肝移植的患者与实施后接受肝移植的患者进行比较。主要结局是任何血液成分的输血情况。次要结局包括:红细胞(RBC)、新鲜冰冻血浆(FFP)、冷沉淀或血小板的输血情况、临床并发症、住院时间和院内死亡率。
对照组共纳入183例患者,干预组纳入54例患者。倾向评分匹配后,干预组接受任何血液成分输血的患者比例较低(37.0%对58.4%;OR,0.42;95%CI,0.20 - 0.87;p = 0.019)。干预组患者接受的RBC较少(30.2%对52.5%;OR,0.21;95%CI,0.08 - 0.56;p = 0.002),FFP也较少(5.7%对27.3%;OR,0.11;95%CI,0.03 - 0.43;p = 0.002)。冷沉淀和血小板的输血情况、与手术相关的并发症、住院时间和死亡率方面没有差异。
使用合成凝血因子浓缩物的粘弹性试验指导输血算法可降低肝移植患者异体血的输血率。
本试验于2018年11月15日进行回顾性注册 - clinicaltrials.gov - 标识符:NCT03756948。